Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study

Radiotherapy and Oncology

Volumn 120, Issue 3, 2016, Pages 434-440

  Fokdal, Lars ^a   Sturdza, Alina ^b   Mazeron, Renaud ^c   Haie Meder, Christine ^c   Tan, Li Tee ^d   Gillham, Charles ^e   Šegedin, Barbara ^f   Jürgenliemk Schultz, Ina ^g   Kirisits, Christian ^b   Hoskin, Peter ^h   Pötter, Richard ^b   Lindegaard, Jacob C ^a   Tanderup, Kari ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e ST LUKE S HOSPITAL   (Ireland)

^f INSTITUTE OF ONCOLOGY   (Slovenia)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Cervical cancer; Image guided adaptive radiotherapy; Local control; Morbidity

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; IMAGE GUIDED ADAPTIVE BRACHYTHERAPY; IMAGE GUIDED RADIOTHERAPY; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RADIATION APPLICATOR; RADIATION DOSE ESCALATION; THERAPEUTIC INDEX; UTERINE CERVIX CANCER; CLINICAL TRIAL; INTERVENTIONAL RADIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FEMALE; HUMANS; MIDDLE AGED; RADIOLOGY, INTERVENTIONAL; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84963958972     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.03.020     Document Type: Article

References (25)

1. [1] Charra-Brunaud, C., Harter, V., Delannes, M., et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol 103 (2012), 305–313.
2. [2] Lindegaard, J.C., Fokdal, L.U., Nielsen, S.K., Juul-Christensen, J., Tanderup, K., MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol 52 (2013), 1510–1519.
3. [3] Nomden, C.N., de Leeuw, A.A., Roesink, J.M., et al. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. Radiother Oncol 107 (2013), 69–74.
4. [4] Pötter, R., Dimopoulos, J., Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100 (2011), 116–123.
5. [5] Chargari, C., Magne, N., Dumas, I., et al. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 74 (2009), 133–139.
6. [6] Gill, B.S., Lin, J.F., Krivak, T.C., et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 90 (2014), 1083–1090.
7. [7] Mazeron, R., Gilmore, J., Dumas, I., et al. Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer. Oncologist 18 (2013), 415–422.
8. [8] Rijkmans, E.C., Nout, R.A., Rutten, I.H., et al. Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol 135 (2014), 231–238.
9. [9] Tan, L.T., Zahra, M., Long-term survival and late toxicity after chemoradiotherapy for cervical cancer–the Addenbrooke's experience. Clin Oncol (R Coll Radiol) 20 (2008), 358–364.
10. [10] Tanderup, K., Potter, R., Lindegaard, J.C., Berger, D., Wambersie, A., Kirisits, C., PTV margins should not be used to compensate for uncertainties in 3D image guided intracavitary brachytherapy. Radiother Oncol 97 (2010), 495–500.
11. [11] Lindegaard, J.C., Tanderup, K., Nielsen, S.K., Haack, S., Gelineck, J., MRI-guided 3D optimization significantly improves DVH parameters of pulsed dose rate brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 71 (2008), 756–764.
12. [12] Jurgenliemk-Schulz, I.M., Tersteeg, R.J., Roesink, J.M., et al. MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer. Radiother Oncol 93 (2009), 322–330.
13. [13] Tanderup, K., Nielsen, S.K., Nyvang, G., et al. From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer. Radiother Oncol 94 (2010), 173–180.
14. [14] Haie-Meder, C., Potter, R., van Limbergen, E., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group() (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74 (2005), 235–245.
15. [15] Pötter, R., Haie-Meder, C., Limbergen, E.V., et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78 (2006), 67–77.
16. [16] Kirisits, C., Lang, S., Dimopoulos, J., Berger, D., Georg, D., Potter, R., The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: design, application, treatment planning, and dosimetric results. Int J Radiat Oncol Biol Phys 65 (2006), 624–630.
17. [17] Dimopoulos, J.C., Kirisits, C., Petric, P., et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: clinical feasibility and preliminary results. Int J Radiat Oncol Biol Phys 66 (2006), 83–90.
18. [18] Fokdal, L., Tanderup, K., Hokland, S.B., et al. Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component. Radiother Oncol 107 (2013), 63–68.
19. [19] Nomden, C.N., de Leeuw, A.A., Moerland, M.A., Roesink, J.M., Tersteeg, R.J., Jurgenliemk-Schulz, I.M., Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys, 2011.
20. [20] Mohamed, S., Kallehauge, J., Fokdal, L., Lindegaard, J.C., Tanderup, K., Parametrial boosting in locally advanced cervical cancer: combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy. Brachytherapy 14 (2015), 23–28.
21. [21] Fenkell, L., Assenholt, M., Nielsen, S.K., et al. Parametrial boost using midline shielding results in an unpredictable dose to tumor and organs at risk in combined external beam radiotherapy and brachytherapy for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 79 (2011), 1572–1579.
22. [22] Lindegaard, J.C., Tanderup, K., Counterpoint: time to retire the parametrial boost. Brachytherapy 11 (2012), 80–83.
23. [23] Schmid, M.P., Kirisits, C., Nesvacil, N., Dimopoulos, J.C., Berger, D., Potter, R., Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis. Radiother Oncol 100 (2011), 468–472.
24. [24] Westerveld, H., Potter, R., Berger, D., et al. Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy. Radiother Oncol 107 (2013), 99–105.
25. [25] Rose, P.G., Java, J., Whitney, C.W., et al. Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG Oncology/Gynecologic Oncology Group randomized trials of chemoradiotherapy. J Clin Oncol 33 (2015), 2136–2142.